ArticleCureus2022
Huge Right Retroperitoneal Paraganglioma With a High Risk of Surgical Excision Treated Conservatively for 14 Years.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraganglioma is an uncommon type of neuroendocrine tumor capable of secreting neuropeptides and catecholamines. Retroperitoneal paragangliomas are rare neoplasms that originate from chromaffin cells that secrete catecholamines in the sympathetic ganglia. Tumor reduction and management of excessive catecholamine secretion are the key treatment goals. Surgery is the choice of treatment modality when tumors are amenable to resection because of their malignant potential. Currently, high-dose metaiodobenzylguanidine (MIBG) radiation and chemotherapy are adjuvant therapy to surgery. This case is reported to demonstrate a good prognosis in a conservatively managed, huge, non-functional retroperitoneal paraganglioma for 14 years. This provides alternative options to the traditional surgical treatment in patients who refuse, are unfit for surgery, or have complex surgery, which carries a high mortality rate with analysis of follow-up modalities. Meanwhile, a review of the relevant literature was conducted in order to figure out the prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.